Andrew Cheng - Nov 2, 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: President & CEO, Director
Signature: /s/ Jonathan Young, Attorney-in-Fact
Stock symbol: AKRO
Transactions as of: Nov 2, 2021
Transactions value $: -$394,975
Form type: 4
Date filed: 11/3/2021, 04:16 PM
Previous filing: Oct 5, 2021
Next filing: Dec 3, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Sale	-$395K	-17.5K	-6.01%	$22.57	273K	Nov 2, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 26, 2021, previously adopted by the reporting person.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.40 to $23.09, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Content

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 26, 2021, previously adopted by the reporting person.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.40 to $23.09, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.